RxIndia
Loading clinical data...
Loading clinical data...
Verified clinical guidelines and emergency management protocols.
| Procedure/Action | Primary Care | Secondary/Tertiary Care |
|---|---|---|
| Recognition of toxidrome |
β
|
β
|
| Decontamination |
β
|
β
|
| Airway protection |
β
|
β
|
| IV access & fluids |
β
|
β
|
| Atropine therapy (OP/Carbamate) |
β
|
β
|
| Pralidoxime (2-PAM) |
β οΈ (if available)
|
β
|
| Gastric lavage |
β οΈ (with caution)
|
β
|
| Mechanical ventilation |
β
|
β
|
| Hemodialysis |
β
|
β
|
| ICU-level monitoring |
β
|
β
|
| Milestone | Target Time |
|---|---|
| Remove contaminated clothing |
Immediate
|
| Decontamination (skin/eye wash) |
Immediate
|
| Secure airway if compromised |
Immediate
|
| IV access |
≤ 5 min
|
| Start Atropine (OP/Carbamate) |
≤ 10 min
|
| Start Pralidoxime (OP) |
≤ 6 hours (ideally ≤ 4 hours)
|
| Transfer to higher centre |
ASAP after stabilization
|
| Poison | Mechanism | Onset | Antidote | Mortality |
|---|---|---|---|---|
|
Organophosphate (OP)
|
Irreversible AChE inhibition |
30 min - 12 hrs
|
Atropine + Pralidoxime
|
10-40%
|
|
Carbamate
|
Reversible AChE inhibition |
15 min - 2 hrs
|
Atropine only
|
5-10%
|
|
Aluminum Phosphide (Celphos)
|
Phosphine gas → mitochondrial toxicity |
30 min - 6 hrs
|
β NONE
|
40-90%
|
|
Paraquat
|
Oxidative stress → pulmonary fibrosis |
Hours to days
|
β NONE
|
50-90%
|
|
Pyrethroid
|
Sodium channel modulation |
30 min - 2 hrs
|
Supportive
|
< 5%
|
| Category | Common Products / Trade Names |
|---|---|
|
Organophosphates
|
Monocrotophos, Phorate, Methyl Parathion, Chlorpyrifos, Malathion, Dimethoate, Quinalphos |
|
Carbamates
|
Carbofuran (Furadan), Carbaryl (Sevin), Propoxur (Baygon), Aldicarb |
|
Aluminum Phosphide
|
Celphos, Quickphos, Alphos, Phosphume, Rice tablets |
|
Paraquat
|
Gramoxone, Parazone |
|
Pyrethroids
|
Cypermethrin, Deltamethrin, Permethrin, Allethrin |
| β οΈ Risk | Precaution |
|---|---|
|
Skin contamination
|
Wear gloves (double-gloving preferred), gown, apron |
|
Inhalation (especially AlP)
|
Well-ventilated area; face mask; avoid enclosed spaces |
|
Eye splash
|
Eye protection / goggles |
|
Secondary contamination
|
Remove patient's clothing before entering ED |
|
Vomitus
|
Highly toxic – handle with care, dispose safely |
| Question | Why Important |
|---|---|
|
What substance was taken?
|
Bring container/label if available |
|
How much was taken?
|
Dose estimation |
|
When was it taken?
|
Time to intervention |
|
Route of exposure?
|
Ingestion, inhalation, dermal |
|
Intentional or accidental?
|
Psychiatric assessment needed |
|
Any vomiting?
|
May have expelled some poison |
|
Any treatment given before arrival?
|
Home remedies, other facilities |
|
Past medical history?
|
Comorbidities affecting management |
| Letter | Sign |
|---|---|
|
S
|
Salivation |
|
L
|
Lacrimation |
|
U
|
Urination |
|
D
|
Defecation / Diarrhea |
|
G
|
GI cramps |
|
E
|
Emesis |
|
---
|
--- |
|
B
|
Bronchorrhea |
|
B
|
Bronchospasm |
|
B
|
Bradycardia |
| Letter | Sign |
|---|---|
|
D
|
Diarrhea |
|
U
|
Urination |
|
M
|
Miosis (pinpoint pupils) |
|
B
|
Bronchorrhea / Bronchospasm / Bradycardia |
|
E
|
Emesis |
|
L
|
Lacrimation |
|
S
|
Salivation |
| Effect | Signs |
|---|---|
|
Muscle
|
Fasciculations, weakness, paralysis |
|
Cardiovascular
|
Tachycardia, hypertension (may override muscarinic bradycardia) |
|
CNS
|
Anxiety, restlessness, seizures, coma |
| Effect |
|---|
| Anxiety, agitation |
| Confusion |
| Seizures |
| Coma |
| Respiratory depression |
| System | Signs & Symptoms |
|---|---|
|
GI
|
Severe burning epigastric pain, nausea, vomiting (garlic/fish odor) |
|
Cardiovascular
|
Profound hypotension, shock (most common cause of death) |
| Arrhythmias (VT, VF, heart block) | |
| Myocarditis | |
|
Respiratory
|
Dyspnea, pulmonary edema, ARDS |
|
CNS
|
Agitation, dizziness, headache, seizures, coma |
|
Metabolic
|
Severe metabolic acidosis |
|
Renal
|
Acute kidney injury |
|
Hepatic
|
Hepatic injury |
| Phase | Timing | Features |
|---|---|---|
|
Phase 1
|
0-24 hrs
|
GI corrosive injury: oral/esophageal burns, vomiting, diarrhea |
|
Phase 2
|
24-72 hrs
|
Multi-organ damage: hepatic, renal, cardiac injury |
|
Phase 3
|
Days to weeks
|
Pulmonary fibrosis (progressive, irreversible)
|
| Key Feature |
|---|
|
Oral mucosal ulceration ("Paraquat tongue") – burns in mouth/throat
|
| Delayed respiratory failure (days to weeks) |
| High FiOβ worsens lung injury (avoid excess Oβ) |
| Type | Symptoms |
|---|---|
|
Type I (without cyano group)
|
Tremors, hyperexcitability, ataxia |
|
Type II (with cyano group – e.g., Cypermethrin)
|
Choreoathetosis, salivation, seizures |
|
Allergic
|
Dermatitis, rhinitis, bronchospasm |
|
Severity
|
Usually mild; rarely life-threatening |
| Feature | Organophosphate | Carbamate | Aluminum Phosphide |
|---|---|---|---|
|
AChE inhibition
|
Irreversible
|
Reversible
|
No AChE effect
|
|
Cholinergic toxidrome
|
β
Prominent
|
β
Prominent
|
β Absent
|
|
Miosis
|
β
Yes
|
β
Yes
|
β No (or late dilated pupils)
|
|
Garlic/fish odor
|
β No
|
β No
|
β
Yes
|
|
Shock
|
Late
|
Late
|
β
Early, profound
|
|
Metabolic acidosis
|
Mild-moderate
|
Mild
|
β
Severe
|
|
Pralidoxime useful?
|
β
Yes
|
β No
|
β No
|
|
Atropine useful?
|
β
Yes
|
β
Yes
|
β No
|
| Action | Details |
|---|---|
|
Don PPE
|
Gloves, gown, mask, eye protection |
|
Well-ventilated area
|
Critical for AlP (phosphine gas) |
|
Remove all clothing
|
Place in plastic bag; dispose safely |
|
Skin decontamination
|
Wash entire body with soap and water |
|
Hair washing
|
Shampoo thoroughly |
|
Eye decontamination
|
Irrigate with NS or water for 15-20 min (if eye exposure) |
|
Avoid contaminating yourself
|
Handle patient carefully |
| Action | Details |
|---|---|
|
Airway
|
Suction secretions (copious in OP); position patient |
|
Oxygen
|
If SpOβ < 94% (but use cautiously in Paraquat – avoid high FiOβ) |
|
IV Access
|
2 large-bore cannulas |
|
Fluids
|
NS bolus if hypotensive (especially AlP) |
|
Monitor
|
BP, HR, SpOβ, GCS, pupils |
|
Intubation
|
If GCS < 8, severe respiratory secretions, impending failure |
| Poison | Gastric Lavage Indicated? | Notes |
|---|---|---|
|
Organophosphate
|
β οΈ May consider within 1-2 hrs
|
Only if airway protected; controversy exists |
|
Carbamate
|
β οΈ May consider within 1 hr
|
Less benefit than OP |
|
Aluminum Phosphide
|
β οΈ May consider ONLY with KMnOβ or NaHCOβ
|
Controversial; risk of aspiration; may increase phosphine release |
|
Paraquat
|
β
Yes – within 1-2 hrs
|
Fuller's earth or Activated charcoal |
|
Pyrethroid
|
β οΈ Rarely needed
|
Usually mild |
| Contraindication |
|---|
| Altered consciousness without airway protection |
| Corrosive ingestion (acid/alkali) |
| > 2 hours since ingestion (limited benefit) |
| Convulsions (uncontrolled) |
| Poison | Activated Charcoal Useful? | Dose |
|---|---|---|
| Organophosphate |
β οΈ Limited evidence
|
1 g/kg (max 50 g)
|
| Carbamate |
β οΈ Limited evidence
|
1 g/kg (max 50 g)
|
| Aluminum Phosphide |
β NOT effective
|
—
|
| Paraquat |
β οΈ May help if early (< 1-2 hrs)
|
1-2 g/kg
|
| Pyrethroid |
β οΈ May help
|
1 g/kg
|
| Step | Action |
|---|---|
| 1 |
Test dose: 1-2 mg IV bolus (adults); 0.02 mg/kg (children)
|
| 2 |
Observe for 3-5 minutes
|
| 3 |
If no atropinization: Double the dose (2-4 mg → 4-8 mg → 8-16 mg...)
|
| 4 |
Repeat every 3-5 min until ATROPINIZATION achieved
|
| 5 |
Once atropinized: Start infusion (10-20% of total loading dose per hour)
|
| Chest clear (no wheeze/crackles) | β Most important |
|---|---|
|
Dry axillae
|
β |
|
Heart rate > 80 bpm
|
β |
|
Systolic BP > 80 mmHg
|
β |
|
Pupils dilated
|
Not a target – occurs late |
| Dose | If No Response |
|---|---|
|
1-2 mg
|
Give 2-4 mg |
|
2-4 mg
|
Give 4-8 mg |
|
4-8 mg
|
Give 8-16 mg |
|
8-16 mg
|
Give 16-32 mg |
|
Continue doubling...
|
May need 100+ mg in severe cases |
| Calculation | Example |
|---|---|
| Infusion rate = 10-20% of total loading dose per hour | If 30 mg needed to atropinize → Infuse 3-6 mg/hr |
| Preparation | Add Atropine to NS in syringe pump |
| Titrate | Increase/decrease to maintain atropinization |
| Duration | May need 24-48 hrs or more |
| Sign | Action |
|---|---|
| Hyperthermia | Reduce dose; cooling |
| Agitation, delirium | Reduce dose; may need sedation |
| Urinary retention | Catheterize |
| Ileus | Reduce dose |
| Tachycardia > 120 (with above signs) | Reduce dose |
| Indication | Give Pralidoxime? |
|---|---|
|
Organophosphate poisoning
|
β
Yes
|
|
Carbamate poisoning
|
β No (reversible inhibition; may worsen)
|
|
Aluminum phosphide
|
β No
|
|
Unknown – but cholinergic toxidrome
|
β
Yes (assume OP)
|
| Timing | Effectiveness |
|---|---|
| < 6 hours | β Most effective |
| 6-24 hours | β οΈ May still be beneficial |
| > 24-48 hours | β Limited benefit (aging has occurred) |
| Population | Loading Dose | Maintenance |
|---|---|---|
|
Adult
|
1-2 g IV over 15-30 min
|
500 mg/hr infusion OR 1-2 g every 4-6 hrs
|
|
Child
|
25-50 mg/kg IV over 15-30 min
|
10-20 mg/kg/hr infusion
|
| Preparation | Details |
|---|---|
| Available as | 500 mg or 1 g vials (powder for reconstitution) |
| Reconstitute | With 20 mL sterile water |
| Dilute | In 100 mL NS for infusion |
| Rate | Over 15-30 min (rapid bolus can cause hypertension, muscle rigidity) |
| Action |
|---|
| Start Atropine (it alone can be life-saving) |
| Pralidoxime can be given at secondary care |
| Transfer urgently |
| Do not delay transfer waiting for Pralidoxime |
| Drug | Dose | Route |
|---|---|---|
|
Diazepam
|
5-10 mg
|
IV slow
|
|
0.2-0.3 mg/kg (child)
|
IV/PR
|
|
|
Midazolam
|
2.5-5 mg
|
IV/IM
|
|
Lorazepam
|
2-4 mg
|
IV
|
| Step | Action |
|---|---|
| 1 | PPE + Decontamination |
| 2 | Airway + Suction (copious secretions) |
| 3 | IV access |
| 4 |
Atropine 1-2 mg IV; double every 3-5 min until dry
|
| 5 |
Pralidoxime 1-2 g IV over 30 min (if available)
|
| 6 | Diazepam for seizures |
| 7 |
TRANSFER to higher centre
|
| Feature | Organophosphate | Carbamate |
|---|---|---|
| AChE inhibition |
Irreversible
|
Reversible
|
| Duration of toxicity |
Prolonged (days)
|
Shorter (hours)
|
| Pralidoxime |
β
Yes
|
β No (may worsen)
|
| Atropine |
β
Yes
|
β
Yes
|
| Recovery |
Slower
|
Faster
|
| Step | Action |
|---|---|
| 1 | Decontamination |
| 2 | Airway + Suction |
| 3 |
Atropine (same protocol as OP)
|
| 4 |
β Do NOT give Pralidoxime
|
| 5 | Supportive care |
| 6 | Transfer if severe |
| Point | Details |
|---|---|
|
Mechanism
|
Phosphine gas (PHβ) → mitochondrial toxicity → cellular hypoxia |
|
Lethal dose
|
150-500 mg (1 tablet can kill) |
|
Antidote
|
β NONE
|
|
Cause of death
|
Cardiogenic shock, arrhythmias, refractory hypotension |
|
Odor
|
Garlic/fish smell of breath/vomitus |
| Step | Action |
|---|---|
| 1 |
Ensure ventilation (open windows, fans) – phosphine gas danger
|
| 2 |
Remove clothing (dispose in open area)
|
| 3 |
Do NOT induce vomiting at primary level
|
| 4 |
IV access × 2
|
| 5 |
IV fluids: NS bolus if hypotensive
|
| 6 |
Oxygen if SpOβ < 94%
|
| 7 |
TRANSFER IMMEDIATELY – this is highest priority
|
| Consideration | Details |
|---|---|
|
If performed
|
Use Potassium permanganate (KMnOβ) 1:10,000 OR Sodium bicarbonate 2%
|
|
Rationale
|
KMnOβ oxidizes phosphine; NaHCOβ reduces absorption |
|
Risk
|
Gastric lavage may increase phosphine release; aspiration risk |
|
Current consensus
|
Controversial; many centres avoid gastric lavage |
|
At primary care
|
Do NOT perform unless trained; prioritize transfer |
| Solution | Preparation |
|---|---|
| KMnOβ 1:10,000 | 100 mg in 1 L water (light pink color) |
| NaHCOβ 2% | 20 g in 1 L water |
| Coconut oil | 100 mL via NG tube (to reduce phosphine release) – limited evidence |
| β Do NOT |
|---|
| Induce vomiting (aspiration risk, more phosphine release) |
| Perform CPR in enclosed space without ventilation |
| Delay transfer for any procedure |
| Give any "antidote" (none exists) |
| Allow patient to lie in enclosed room (phosphine accumulates) |
| Step | Action |
|---|---|
| 1 | Ventilation / Open space |
| 2 | Remove clothing |
| 3 | IV access, IV NS bolus |
| 4 | Oxygen |
| 5 |
TRANSFER IMMEDIATELY
|
| 6 | Pre-alert receiving hospital |
| Point | Details |
|---|---|
|
Mechanism
|
Generates free radicals → oxidative stress → pulmonary fibrosis
|
|
Lethal dose
|
20-40 mg/kg (~10-20 mL of 20% solution) |
|
Antidote
|
β NONE
|
|
Cause of death
|
Pulmonary fibrosis → respiratory failure (days to weeks) |
|
Paradox
|
β οΈ High-dose oxygen WORSENS lung injury
|
| Phase | Timing | Features |
|---|---|---|
|
Immediate
|
0-24 hrs
|
Oropharyngeal/esophageal burns, vomiting, diarrhea, abdominal pain |
|
Intermediate
|
24-72 hrs
|
Hepatic, renal, cardiac injury |
|
Late
|
Days-weeks
|
Progressive pulmonary fibrosis → respiratory failure
|
| Finding | Significance |
|---|---|
| Oral mucosal ulceration | "Paraquat tongue" – suggestive of paraquat |
| Tongue edema, erosions | Corrosive injury |
| Pharyngeal burns | Indicates significant ingestion |
| Step | Action |
|---|---|
| 1 |
Decontamination (skin, remove clothing)
|
| 2 | IV access |
| 3 |
Gastric decontamination (if < 1-2 hrs)
|
| 4 |
Fuller's Earth 15% (100-150 g in 1 L water) via NG tube OR
|
| 5 |
Activated charcoal (1-2 g/kg) if Fuller's Earth unavailable
|
| 6 |
β οΈ Avoid high FiOβ (keep SpOβ 88-92% if possible)
|
| 7 |
TRANSFER IMMEDIATELY
|
| SpOβ | Action |
|---|---|
|
> 92%
|
No supplemental oxygen
|
|
88-92%
|
Tolerate lower SpOβ (to minimize Oβ toxicity)
|
|
< 88% with distress
|
Low-flow Oβ to maintain SpOβ 88-92% |
| β Do NOT |
|---|
| Give high-flow oxygen (worsens pulmonary fibrosis) |
| Delay gastric decontamination |
| Give emetics (risk of re-exposure to esophagus) |
| Point | Details |
|---|---|
|
Mechanism
|
Sodium channel modulators → neuronal hyperexcitability |
|
Toxicity
|
Usually mild (low mammalian toxicity)
|
|
Route
|
Dermal, inhalation, ingestion |
|
Antidote
|
β None (supportive care) |
|
Mortality
|
Very low (< 5%) |
| Type | Compounds | Features |
|---|---|---|
|
Type I (non-cyano)
|
Permethrin, Allethrin, Tetramethrin | Tremor, hyperexcitability, paresthesias |
|
Type II (cyano)
|
Cypermethrin, Deltamethrin, Fenvalerate | Choreoathetosis, salivation, seizures ("CS syndrome") |
|
Allergic
|
Any | Dermatitis, rhinitis, bronchospasm, anaphylaxis (rare) |
| Step | Action |
|---|---|
| 1 |
Decontamination (remove clothing, wash skin with soap and water)
|
| 2 |
Symptomatic treatment
|
| 3 | Diazepam for seizures/tremor |
| 4 | Bronchodilators for bronchospasm |
| 5 | Antihistamines for allergic reactions |
| 6 | Usually does NOT require transfer unless severe |
| Treatment |
|---|
| Wash area with soap and water |
| Apply Vitamin E oil or cream (may reduce paresthesia) |
| Usually resolves in 24-48 hours |
| Poison | Transfer Urgency |
|---|---|
|
Organophosphate (moderate-severe)
|
β
URGENT
|
|
Carbamate (severe)
|
β
URGENT
|
|
Aluminum Phosphide (any)
|
β
IMMEDIATE (highest mortality)
|
|
Paraquat (any)
|
β
URGENT
|
|
Pyrethroid (mild)
|
β οΈ May observe; transfer if severe
|
| Item | Done? |
|---|---|
| Decontamination completed |
β
|
| Airway secure / Secretions suctioned |
β
|
| IV access established |
β
|
| Atropine started (OP/Carbamate) |
β
|
| Pralidoxime given (OP) – if available |
β
|
| Poison/container brought with patient |
β
|
| Time of ingestion documented |
β
|
| Estimated amount ingested documented |
β
|
| All treatment given documented with times |
β
|
| Receiving hospital pre-alerted |
β
|
| Information |
|---|
| Type of poison (bring container if available) |
| Time of ingestion |
| Estimated amount |
| Route (ingestion, dermal, inhalation) |
| Symptoms on presentation |
| Treatment given (especially Atropine dose) |
| Current vitals and GCS |
| Response to treatment |
| Action | Target Time |
|---|---|
| Confirm poison type |
Immediate
|
| Assess airway, breathing, circulation |
Immediate
|
| Check GCS, pupils |
Immediate
|
| Continue/escalate Atropine (OP/Carbamate) |
Ongoing
|
| IV access (if not done) |
Immediate
|
| Draw blood samples |
≤ 15 min
|
| ECG |
≤ 15 min
|
| ABG |
≤ 30 min
|
| Investigation | Purpose |
|---|---|
|
Serum Cholinesterase (Pseudocholinesterase)
|
Confirms OP/Carbamate; monitor recovery |
|
RBC Cholinesterase
|
More specific for OP (if available) |
|
ABG
|
Acidosis, oxygenation |
|
Electrolytes (Na, K, Mg)
|
Correct abnormalities (especially in AlP) |
|
Renal function (Cr, BUN)
|
AKI monitoring |
|
LFT
|
Hepatotoxicity |
|
Blood glucose
|
Hypo/hyperglycemia |
|
ECG
|
Arrhythmias (especially AlP) |
|
Chest X-ray
|
Pulmonary edema, aspiration |
|
Serum Lactate
|
Tissue hypoxia (AlP) |
|
Cardiac enzymes (Troponin)
|
Myocarditis (AlP) |
|
Echocardiography
|
LV function (AlP) |
| Level | Interpretation |
|---|---|
|
Normal
|
Unlikely OP/Carbamate poisoning (or very early) |
|
50-75% of normal
|
Mild poisoning |
|
25-50% of normal
|
Moderate poisoning |
|
< 25% of normal
|
Severe poisoning |
|
< 10% of normal
|
Very severe poisoning |
| Phase | Management |
|---|---|
|
Loading
|
Continue doubling dose every 3-5 min until atropinized |
|
Maintenance
|
Infusion at 10-20% of loading dose per hour |
|
Titration
|
Increase if secretions recur; decrease if toxicity signs |
|
Duration
|
May need 24-72+ hours |
|
Weaning
|
Gradually reduce as patient improves |
| Preparation | Example |
|---|---|
| Add 50-100 mg Atropine to 500 mL NS | 0.1-0.2 mg/mL |
| Titrate infusion rate | To maintain atropinization |
| Regimen | Details |
|---|---|
|
Loading (if not given)
|
1-2 g IV over 30 min |
|
Maintenance
|
500 mg/hr continuous infusion OR 1-2 g every 4-6 hrs |
|
Duration
|
Continue until clinical improvement and atropine weaning |
|
WHO recommendation
|
May continue for 7+ days in severe cases |
| Indication | Action |
|---|---|
| GCS < 8 | Intubate |
| Copious secretions despite atropine | Intubate |
| Respiratory failure | Intubate + Ventilate |
| Anticipate prolonged course | Early intubation |
| Parameter | Target |
|---|---|
| Mode | Volume control or Pressure control |
| Avoid | Succinylcholine (prolonged paralysis due to ↓ cholinesterase) |
| Use | Non-depolarizing NMBAs (if needed) |
| Expect | Prolonged ventilation (days to weeks) |
| Feature | Details |
|---|---|
|
Timing
|
24-96 hours after acute cholinergic crisis has resolved |
|
Cause
|
Persistent neuromuscular junction dysfunction |
|
Features
|
Proximal muscle weakness, neck flexor weakness, respiratory failure, cranial nerve palsies |
|
Mortality
|
High if not recognized (respiratory failure) |
|
Management
|
Supportive; continued ventilation; atropine not helpful |
|
Recovery
|
Days to weeks |
| Feature | Details |
|---|---|
|
Timing
|
2-4 weeks after exposure |
|
Cause
|
Axonal degeneration of long nerves |
|
Features
|
Distal motor weakness (legs > arms), sensory loss, "dying-back" neuropathy |
|
Compounds
|
Certain OPs (triorthocresyl phosphate, chlorpyrifos) |
|
Management
|
Supportive; physiotherapy; may have persistent deficits |
| Complication | Management |
|---|---|
|
Aspiration pneumonia
|
Antibiotics, ventilatory support |
|
Seizures
|
Diazepam; avoid phenytoin |
|
Arrhythmias
|
Treat per ACLS; correct electrolytes |
|
Pulmonary edema
|
PEEP, diuretics if cardiogenic |
|
Rhabdomyolysis
|
IV fluids, monitor CK, prevent AKI |
| Principle | Details |
|---|---|
|
Aggressive fluid resuscitation
|
Treat profound hypovolemia |
|
Vasopressors
|
Often required (refractory shock) |
|
Correct metabolic acidosis
|
NaHCOβ for severe acidosis |
|
Correct electrolytes
|
Especially Mg²βΊ (hypomagnesemia common) |
|
Cardiac support
|
Inotropes, treat arrhythmias |
|
Multi-organ support
|
Ventilation, dialysis as needed |
| Action | Details |
|---|---|
| Initial bolus | NS or RL 20-30 mL/kg |
| Reassess | If still hypotensive → continue boluses |
| Target | MAP ≥ 65 mmHg, UOP > 0.5 mL/kg/hr |
| Caution | May develop pulmonary edema – monitor closely |
| Drug | Dose | Notes |
|---|---|---|
|
Norepinephrine
|
0.1-1+ μg/kg/min
|
First-line vasopressor |
|
Dopamine
|
5-20 μg/kg/min
|
Alternative |
|
Dobutamine
|
5-20 μg/kg/min
|
If low cardiac output |
|
Vasopressin
|
0.03-0.04 U/min
|
Add if refractory |
| Rationale | Details |
|---|---|
| Hypomagnesemia common | Phosphine depletes Mg²βΊ |
| Cardioprotective | Anti-arrhythmic |
| Vasodilatory | May improve perfusion |
| Dose | 1-2 g IV bolus → 1-2 g/hr infusion |
| Target | Serum Mg 3-4 mg/dL |
| Indication | Dose |
|---|---|
| Severe metabolic acidosis (pH < 7.1) |
50-100 mEq IV bolus
|
| Target |
pH > 7.2
|
| Caution |
May cause hypokalemia, volume overload
|
| Rationale | Details |
|---|---|
| Antioxidant | May counteract oxidative stress |
| Evidence | Limited; some case reports suggest benefit |
| Dose | 150 mg/kg IV over 1 hr → 50 mg/kg over 4 hrs → 100 mg/kg over 16 hrs |
| Recommendation | May be tried; not standard of care |
| Arrhythmia | Management |
|---|---|
| VT/VF | Defibrillation, Amiodarone 150-300 mg IV |
| Bradycardia | Atropine 0.5-1 mg IV; Pacing if refractory |
| Torsades de Pointes | IV Magnesium 2 g; Correct KβΊ |
| Therapy | Rationale | Evidence Level |
|---|---|---|
|
Magnesium sulfate
|
Cardioprotective |
Moderate
|
|
N-Acetylcysteine
|
Antioxidant |
Low
|
|
Coconut oil (NG)
|
Reduce phosphine release |
Very low
|
|
Intra-aortic balloon pump (IABP)
|
Refractory cardiogenic shock |
Case reports
|
|
ECMO
|
Refractory shock |
Case reports
|
|
Triiodothyronine (T3)
|
May improve cardiac function |
Very low
|
| Good Prognosis | Poor Prognosis |
|---|---|
| Fresh tablet (exposed to air = less phosphine) | Unexposed / new tablet |
| Vomiting occurred early | No vomiting |
| Small amount ingested | Large amount (> 1 tablet) |
| Arrived early (< 2 hrs) | Delayed presentation |
| No shock on arrival | Shock at presentation |
| Mild metabolic acidosis | Severe acidosis (pH < 7.1) |
| Preserved consciousness | Coma |
| β Do NOT |
|---|
| Give any specific "antidote" (none exists) |
| Delay aggressive fluid resuscitation |
| Forget magnesium supplementation |
| Give up early – survival is possible with aggressive support |
| Principle | Details |
|---|---|
|
Limit oxygen exposure
|
Oβ accelerates pulmonary fibrosis |
|
Early GI decontamination
|
Fuller's earth / Activated charcoal |
|
Hemodialysis/Hemoperfusion
|
May help if early (< 4 hrs) |
|
Immunosuppression
|
Controversial; may reduce fibrosis |
|
Supportive care
|
Fluid, nutrition, treat complications |
| Agent | Dose | Notes |
|---|---|---|
|
Fuller's Earth 15%
|
100-150 g in 1 L water via NG
|
Adsorbs paraquat; give ASAP |
|
Activated Charcoal
|
1-2 g/kg
|
If Fuller's Earth unavailable |
|
Repeat doses
|
Every 2-4 hrs × 3-4 doses
|
Continue adsorption |
|
Cathartic
|
Magnesium sulfate 250 mg/kg or Mannitol 20%
|
Promote GI elimination |
| SpOβ | Management |
|---|---|
|
> 92%
|
No supplemental Oβ
|
|
88-92%
|
Tolerate – avoid Oβ if possible
|
|
< 88% with distress
|
Low-flow Oβ (1-2 L/min) to maintain SpOβ 88-92%
|
|
Severe hypoxia
|
Use minimum FiOβ necessary; avoid > 21% if possible |
| Method | Effectiveness | When to Consider |
|---|---|---|
|
Hemodialysis
|
β οΈ Limited
|
If < 4 hrs post-ingestion; renal failure |
|
Hemoperfusion (Charcoal)
|
β οΈ May help early
|
If < 4 hrs post-ingestion |
|
Continuous RRT
|
β οΈ Limited
|
For renal failure support |
| Protocol | Details |
|---|---|
|
Cyclophosphamide + Methylprednisolone
|
"Pulse therapy" regimen |
| Cyclophosphamide | 15 mg/kg/day IV × 2 days |
| Methylprednisolone | 1 g IV daily × 3 days → taper |
| Evidence | Mixed; some studies show reduced mortality if given early |
| Recommendation | Consider in moderate-severe cases; discuss with toxicologist |
| Parameter | Frequency |
|---|---|
| SpOβ |
Continuous
|
| RFT |
Daily
|
| LFT |
Daily
|
| Chest X-ray |
Daily initially
|
| ABG |
As needed (avoid routine if stable)
|
| SIPP Value | Prognosis |
|---|---|
|
< 10
|
Likely to survive |
|
10-50
|
Guarded |
|
> 50
|
High mortality |
| Large ingestion (> 40 mL of 20% solution) | Very high mortality |
|---|---|
| Oral mucosal ulceration severe | Significant absorption |
| Early respiratory failure | Poor |
| Renal failure | Poor |
| Delayed presentation | Poor |
| Parameter | Frequency |
|---|---|
| Vitals (HR, BP, RR, SpOβ) |
Continuous
|
| GCS |
Hourly
|
| Urine output |
Hourly
|
| Blood glucose |
4-6 hourly
|
| Electrolytes |
6-12 hourly
|
| ABG |
As indicated
|
| Serum Cholinesterase (OP) |
Daily until improving
|
| Lactate (AlP) |
4-6 hourly
|
| Aspect | Recommendation |
|---|---|
| Route | Enteral preferred (unless contraindicated) |
| Timing | Within 24-48 hrs if stable |
| Caution in Paraquat | Oral/esophageal burns may limit enteral route |
| Aspect | Action |
|---|---|
|
Psychiatric assessment
|
All intentional self-harm cases |
|
1:1 supervision
|
Suicide precautions |
|
Family counseling
|
Support and education |
|
Social work referral
|
Address underlying stressors |
|
Safe discharge planning
|
Remove access to poisons at home |
| Criterion | Met? |
|---|---|
| Hemodynamically stable |
β
|
| Off vasopressors |
β
|
| Respiratory stable (no supplemental Oβ or minimal) |
β
|
| Eating and drinking |
β
|
| No ongoing atropine requirement |
β
|
| Cholinesterase recovering (OP) |
β
|
| Psychiatric clearance (if intentional) |
β
|
| Follow-up arranged |
β
|
| Appointment | Timing |
|---|---|
| General physician |
1-2 weeks
|
| Pulmonologist (Paraquat survivors) |
2-4 weeks and ongoing
|
| Neurologist (if OPIDN suspected) |
2-4 weeks
|
| Psychiatrist (if intentional) |
Within 1 week
|
| Topic | Details |
|---|---|
| Safe storage of pesticides | Locked, labeled, away from living areas |
| Avoid decanting into food/drink containers | Common cause of accidental ingestion |
| Protective equipment | Use when handling pesticides |
| Seek help for mental distress | Helpline numbers |
| Warning signs to return | Weakness, breathing difficulty, confusion |
| Step | Action |
|---|---|
| 1 |
Test dose: 1-2 mg IV
|
| 2 | Wait 3-5 min |
| 3 |
If not atropinized: DOUBLE the dose
|
| 4 | Repeat every 3-5 min |
| 5 |
Target: Clear chest, dry axillae, HR > 80, SBP > 80
|
| 6 |
Maintenance: 10-20% of loading dose per hour
|
| Atropinization Targets |
|---|
| β Chest clear (most important) |
| β Dry axillae |
| β HR > 80 bpm |
| β SBP > 80 mmHg |
| β Pupil dilation (NOT a target) |
| Population | Loading Dose | Maintenance |
|---|---|---|
| Adult |
1-2 g IV over 30 min
|
500 mg/hr infusion
|
| Child |
25-50 mg/kg IV over 30 min
|
10-20 mg/kg/hr
|
| Key Points |
|---|
| β Give within 6 hrs of exposure (best < 4 hrs) |
| β Give WITH Atropine (synergistic) |
| β Do NOT give in Carbamate poisoning |
| β Slow infusion (rapid can cause hypertension, rigidity) |
| Key Point | Action |
|---|---|
|
Antidote
|
β NONE |
|
Fluids
|
Aggressive IV NS boluses |
|
Vasopressors
|
Norepinephrine early if shock |
|
Magnesium
|
1-2 g IV bolus → infusion |
|
Bicarbonate
|
If pH < 7.1 |
|
Mortality
|
40-90% |
| Key Point | Action |
|---|---|
|
Antidote
|
β NONE |
|
GI decontamination
|
Fuller's Earth / Activated Charcoal early |
|
Oxygen
|
β οΈ AVOID – worsens lung injury |
|
Target SpOβ
|
88-92% (tolerate lower) |
|
Death
|
Pulmonary fibrosis (days-weeks) |
| β NEVER | β ALWAYS |
|---|---|
| Touch patient without PPE | Decontaminate patient first |
| Fear large Atropine doses (OP) | Give until secretions dry |
| Give Pralidoxime in Carbamate | Give Pralidoxime in OP |
| Give high Oβ in Paraquat | Keep SpOβ 88-92% in Paraquat |
| Expect antidote for AlP | Give aggressive supportive care |
| Perform CPR in closed room (AlP) | Ensure ventilation (phosphine gas) |
| Delay transfer for procedures | Transfer early in severe cases |
| Discharge without psychiatric assessment (intentional) | Assess and refer all intentional cases |
| Feature | OP | Carbamate | AlP | Paraquat |
|---|---|---|---|---|
| Cholinergic toxidrome |
β
|
β
|
β
|
β
|
| Garlic odor |
β
|
β
|
β
|
β
|
| Oral burns |
β
|
β
|
β
|
β
|
| Atropine helpful |
β
|
β
|
β
|
β
|
| Pralidoxime helpful |
β
|
β
|
β
|
β
|
| Avoid Oβ |
β
|
β
|
β
|
β
|
| Abbreviation | Full Form |
|---|---|
|
OP
|
Organophosphate |
|
AChE
|
Acetylcholinesterase |
|
2-PAM
|
Pralidoxime (Pyridine-2-aldoxime methiodide) |
|
AlP
|
Aluminum Phosphide |
|
SLUDGE
|
Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis |
|
DUMBELS
|
Diarrhea, Urination, Miosis, Bronchorrhea/Bradycardia, Emesis, Lacrimation, Salivation |
|
PPE
|
Personal Protective Equipment |
|
IMS
|
Intermediate Syndrome |
|
OPIDN
|
Organophosphate-Induced Delayed Neuropathy |
|
GCS
|
Glasgow Coma Scale |
|
ABG
|
Arterial Blood Gas |
|
NS
|
Normal Saline |
|
RL
|
Ringer's Lactate |
|
NG
|
Nasogastric |
|
KMnOβ
|
Potassium Permanganate |
|
NaHCOβ
|
Sodium Bicarbonate |
|
MgSOβ
|
Magnesium Sulfate |
|
NAC
|
N-Acetylcysteine |
|
IABP
|
Intra-Aortic Balloon Pump |
|
ECMO
|
Extracorporeal Membrane Oxygenation |
|
RRT
|
Renal Replacement Therapy |
|
SIPP
|
Severity Index of Paraquat Poisoning |
|
MAP
|
Mean Arterial Pressure |
|
UOP
|
Urine Output |
|
CK
|
Creatine Kinase |
|
AKI
|
Acute Kidney Injury |
|
ARDS
|
Acute Respiratory Distress Syndrome |
|
VT/VF
|
Ventricular Tachycardia/Ventricular Fibrillation |
| Guideline/Source | Year |
|---|---|
| WHO Guidelines on Prevention and Management of Pesticide Poisoning | 2020 |
| Eddleston M, et al. Management of Acute Organophosphorus Pesticide Poisoning. Lancet | 2008 |
| NPIC (National Poison Information Centre, AIIMS) Guidelines |
Current
|
| API Textbook of Medicine |
Latest
|
| Toxicology Handbook (Australia) | 2021 |
| Nelson's Textbook of Toxicology |
Latest
|
| Journal of Association of Physicians of India (JAPI) – Celphos Poisoning Reviews |
Various
|
| Indian Journal of Critical Care Medicine – Pesticide Poisoning |
Various
|
Medical Advisory
Clinical guidelines are subject to change. Physicians should exercise their regular clinical judgment. This protocol does not replace individual institutional policies. Verified for Q1 2026.
Help us improve our clinical database for the medical community.